ABT-773 was tested against 317 fastidious isolates; it inhibited 99% of organisms at a concentration of 4.0 g/ml. With ampicillin-sulbactam and levofloxacin, only 2 and 6% of these strains, respectively, were resistant at the breakpoint. With clindamycin, penicillin G, and metronidazole, 22, 26, and 58% of the strains, respectively, were resistant.
ABT-773 is a new ketolide antibiotic, a semisynthetic derivative of erythromycin A. Ketolides are more acid stable than macrolides or azalides (4) . ABT-773 has good activity against gram-positive organisms, some gram-negative organisms, and intracellular bacteria. It is initially being developed as an agent for respiratory infections (2) .
Several studies have shown good activity of this compound against several different groups of anaerobic bacteria (1, 3, 5, 7) , but there is little data on the organisms reported on in this study. The present report describes the activity of ABT-773 against a variety of microaerophilic and fastidious bacteria compared to that of five other agents.
All bacteria were recent isolates, primarily from clinically significant infections in patients at the Greater Los Angeles VA Healthcare Center. Bacteria were identified according to established procedures (6) . MICs were determined by the agar dilution technique using an inoculum of 10 5 CFU and Brucella base laked sheep blood agar for most organisms studied, Mueller-Hinton agar with 5% sheep blood for Eikenella, and Haemophilus test medium for Actinobacillus. Plates were incubated in GasPak jars (BBL, Cockeysville, Md.) or in an anaerobic chamber (Anaerobe Systems, San Jose, Calif.) for 48 h at 37°C. MICs were defined as the lowest concentrations of antimicrobial permitting no growth, one discrete colony, a barely visible haze, or any distinct change from the growth control. Antimicrobial agents were obtained as powders Results of the susceptibility tests are presented in Table 1 . Current susceptibility testing techniques are considered to be accurate within one twofold dilution. MICs may cluster at or near breakpoints, so excessive importance should not be placed on differences of a few percentage points at a specific (e.g., breakpoint) concentration. Therefore, the percent susceptible is reported at a range of concentrations from one twofold dilution below to one twofold dilution above the breakpoints of the drugs tested, which are as follows: ampicillinsulbactam, 16 g/ml; clindamycin, 4 g/ml; levofloxacin, 4 g/ ml; metronidazole, 16 g/ml; and penicillin G, 1 g/ml. A breakpoint has not yet been established for ABT-773, so data were analyzed by calculating the percentage of strains susceptible at 4 g/ml. The NCCLS has not established breakpoints for the organisms tested in this study; the breakpoints noted are those for anaerobes, which are also fastidious organisms. Also, when interpreting this data it should be kept in mind that ABT-773 has high protein binding activity (90%).
Overall, ABT-773 showed excellent activity against this group of organisms, inhibiting 99% of the organisms at 4.0 g/ml, with only one strain each of Leptotrichia, Selenomonas, Campylobacter rectus, and Streptococcus intermedius being resistant at that level (but inhibited by 8 g/ml). Furthermore, 100% of the strains tested from the following groups were inhibited at 2 g/ml or less: Desulfomonas species, Mitsuokella species, Capnocytophaga ochracea and Capnocytophaga species, Campylobacter curvus and Campylobacter species (including two Campylobacter showae and one Campylobacter sputorum), Eikenella corrodens, Gardnerella vaginalis, Actinomyces species, Propionibacterium propionicus, Gemella morbillorum, Streptococcus anginosus, Streptococcus constellatus, and the Streptococcus milleri group.
Ampicillin-sulbactam and levofloxacin showed good activity, with only 2 and 6% of strains, respectively, resistant at the breakpoint. However, for clindamycin, penicillin G, and metronidazole, 22, 26, and 58% of strains, respectively, were resistant at the breakpoint.
Some of our results may be skewed because of relatively small numbers of strains studied in certain cases. On the whole, though, our results are comparable to those obtained in other studies cited in which the same organisms were studied. Principally, this was the S. milleri group studied by Andrews et al. (1) and E. corrodens studied by Goldstein et al. (5) .
Clinical trials will obviously be required to define the role of ABT-773 in treating infections involving the organisms studied here. a 50 and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively. Susceptible category breakpoints: ABT-773, 2 g/ml (arbitrary; no breakpoint established); ampicillin-sulbactam, 8 g/ml; clindamycin, 2 g/ml; levofloxacin, 2 g/ml; metronidazole, 8 g/ml; penicillin G, 0.50 g/ml.
